Description
Allele-specific lowering of mutant polyQ proteins as treatment for Huntington disease, spinocerebellar ataxia type 3 and spinocerebellar ataxia type 7
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02017-11-01$443,216
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2017-11-01(start date) | $443,216 | — | Allele-specific lowering of mutant polyQ proteins as treatment for Huntington disease, spinocerebellar ataxia… |
Related records · 1
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2017-2018-Q2-00190 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $3,568,457 | FY2018 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2017-2018-Q4-00048 · retrieved 2026-11-14.